Displaying items by tag: medicine

Scientists have made a breakthrough in antibiotic research with Zosurabalpin, a new drug effective against drug-resistant bacteria like Carbapenem-resistant Acinetobacter baumannii (Crab). This discovery, significant in the fight against antibiotic resistance, has shown promising results in mouse models for pneumonia and sepsis and is now progressing to human trials. Crab, a critical pathogen identified by the World Health Organization, is notorious for its resistance to multiple antibiotics. Zosurabalpin, developed by Roche Pharma, is notable as the first new antibiotic for Gram-negative bacteria, known for their protective outer shells, in over fifty years. Research demonstrates that Zosurabalpin disrupts the bacterium's outer membrane, effectively killing it. This breakthrough offers new avenues for antibiotic development against similar bacteria. However, experts like Dr Andrew Edwards and Dr Michael Lobritz emphasise that this is not a complete solution to antimicrobial resistance. The UK's science committee suggests exploring bacteriophages as an alternative treatment, recommending a production facility at the Rosalind Franklin laboratory to facilitate clinical trials.

Matthew Taylor, chief executive of the NHS Confederation, has warned that upcoming strikes by junior doctors could push the NHS to a tipping point early in the new year. The strikes coincide with typical winter pressures, including cold weather illnesses, bed shortages, and increases in norovirus cases, potentially overwhelming the health service. Junior doctors in England have been on strike this week, and are planning a six-day stoppage from 3 January. The strikes have already led to the postponement of outpatient appointments and operations, with Cheltenham general hospital closing its A&E unit due to staff shortages. The dispute centres on their demands for a 35% pay rise. Recent talks between the British Medical Association and the department of health have not resolved the issue. Dr Vivek Trivedi, for the BMA, argues that the Government's offer of an additional 3% pay rise is insufficient. He emphasises that junior doctors need fair pay to prevent them from seeking employment abroad, and believes the public still supports their right to strike.

Australia's medicines regulator has approved using psychedelics to treat depression and PTSD. This will allow magic mushrooms and ecstasy tablets to be prescribed as medicines at a national level. Ecstasy was developed in 1912 as an appetite suppressant in the USA, but was outlawed in the 1970s. It entered Australia as an illegal party drug in the 1980s, giving increased energy levels, empathy, and pleasure. How Australia rolls out clinical prescriptions for both drugs will be closely watched. Initial access to the drugs will be limited and costly. Many say it’s a landmark moment, but the Medical Association and the College of Psychiatrists have expressed serious concerns about psychedelic treatments. A professor of addiction medicine at the University of Sydney wants larger-scale studies and better research. He warned of known risks of fear, panic and re-traumatisation; and unknown risks of long-term side effects with potentially very limited benefits.

Scientists are concerned that vaccines may be less effective against the Indian variant, which could become dominant in the UK by June. The double mutation Covid-19 variant is thought to be behind a sudden surge in cases in India which has overwhelmed hospitals. A total of 182 cases have been detected in the UK, 162 in the five weeks up to 16 April, forcing Boris Johnson to postpone his trip to India and the government to add India to its travel ‘red list’. Viruses regularly mutate but most are insignificant, however, some mutations can make the virus more infectious, deadly or resistant to vaccines. The Indian virus may be one of those - especially because two mutations have come together to help infect cells and evade the immune system.

British / Swedish drugmaker AstraZeneca has announced promising results in developing a vaccine. An early analysis of some of its late-stage clinical trials, conducted in the UK and Brazil, showed that its coronavirus vaccine was 70.4 percent effective in preventing Covid-19, suggesting that the world could eventually have at least three working vaccines - and greater supply - to help curb the pandemic. However, doubts are being expressed about the results of the trials, mainly because they are based on a very small sample of people. British scientists are defending the validity of the findings, and look forward to further evidence becoming available in December. See

On 12 February the Equalities and Human Rights Commission launched a legal challenge against Matt Hancock, secretary of state for health and social care, over the repeated failure to move people with learning disabilities and autism into appropriate accommodation. It stated, ‘We have long-standing concerns about the rights of more than 2,000 people with learning disabilities and autism being detained in secure hospitals, often far away from home and for many years. We have sent a pre-action letter to Mr Hancock, arguing that his department has breached the European Convention of Human Rights by failing to meet the targets set in tts Transforming Care and Building the Right Support programmes. These targets include moving patients from inappropriate in-patient care to community-based settings, and reducing the reliance on in-patient care for people with learning disabilities and autism.’

The British Medical Association is polling members on its policy on assisted suicide. Since 2006 it has been officially opposed to all forms of euthanasia and assisted suicide. However, if that changes as a result of this poll and the BMA goes 'neutral', some will see that as a green light for a dangerous change in the law. Politicians are unquestionably influenced by what medical bodies think, so it is vital for as many BMA members as possible to take the opportunity to express their support for continued opposition. Last week, a large group of doctors spoke out against shifting to neutral. Please join with us in praying that the BMA will remain opposed, and that the plans of those pushing for a law change will be stopped.

The Science and Technology Committee has decided to monitor reporting of clinical trials by universities, and will question those that don’t improve. Clinical trials are the best way to test whether a medicine is safe and effective. They can involve thousands of people, patients and healthy volunteers, and take years to complete. Results from around half of all clinical trials remain hidden. Trials with negative results are twice as likely to remain unreported as those with positive results. This means that people who make decisions about medicines do not have full information about the benefits and risks of treatments we use every day and can dramatically alter how a drug is perceived, leading to unnecessary spending in the NHS. See

A neurodegenerative disease causes the cells of the brain and spinal cord to be lost. The functions of these cells include decision-making and control of movements. Damaged and lost cells are not easily regenerated, so the effects of diseases are devastating for the sufferers of Alzheimer's, Parkinson's, multiple sclerosis and Huntington's. Sufferers pay the price of both emotional and physical pain. Caring for a relative with a neurodegenerative disease can be challenging and difficult, draining emotions and causing stress. However, scientists now believe they have found a drug to stop certain neurodegenerative brain diseases. In 2013 they stopped brain cells dying in an animal for the first time, but it was unsuitable for people. Now two similar drugs have been found which should have the same effect on people’s brains. Clinical trials are expected to start soon, and within two or three years we will know if they are effective and safe.